Hims review 2026: the public-company branded play, examined

Hims is the men's-focused brand of Hims & Hers Health, Inc., a public company trading on the New York Stock Exchange under the ticker HIMS. The company filed its 2017 SEC paperwork as a special-purpose acquisition target, then became publicly traded in early 2021 through a SPAC merger with Oaktree Acquisition Corp. The corporate entity is incorporated in Delaware, headquartered at 2269 Chestnut St in San Francisco, and reports against a calendar fiscal year. The most recent annual report (Form 10-K for fiscal year 2025) was filed with the SEC on 23 February 2026. SEC filings are the authoritative source for any quantitative claim about the company.

The platform was founded in November 2017 by Andrew Dudum (CEO), Jack Abraham, and Hilary Coles — Hims initially launched as a men's-side product addressing erectile dysfunction and hair loss, with Hers following in 2018. The company expanded into mental health and weight loss subsequently, and as of June 2025 self-reports 2.4M+ subscribers across the platform and a network of 400+ U.S.-licensed healthcare providers. The corporate Hims & Hers structure separates Hims (men) from Hers (women, on forhers.com); this review covers the men's surface only.

The product breadth is the widest in our set. Hims covers weight loss (FDA-approved GLP-1s primarily — Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro), sexual health (sildenafil and tadalafil generics plus branded Viagra and Cialis), hair regrowth (a mix of FDA-approved oral finasteride and oral minoxidil alongside compounded "Hair Hybrids"), mental health (sertraline, escitalopram), testosterone support (enclomiphene and supplements), and lab testing (a 130+ biomarker panel plus a multi-cancer signal test).

The defining strategic move of the past 18 months is the GLP-1 pivot. As the FDA's enforcement timeline closed in on mass-compounding of semaglutide and tirzepatide (see section 06), Hims aggressively repositioned toward branded manufacturer-direct partnerships — NovoCare Pharmacy for Wegovy and Ozempic, LillyDirect for Zepbound and Foundayo. The current GLP-1 menu is almost entirely FDA-approved branded, which is structurally different from the compounded-DTC providers covered elsewhere in our set.

Hims's weight-loss pricing is the most-multi-layered we've seen. There are two cost components — a membership fee and a separate medication fee — and within each medication there are two tiers: a partner-pricing tier (via LillyDirect or NovoCare) and a full-retail tier. The membership fee has a first-month promo and a recurring rate, and the medication "From $X/mo" labels in the page hero footnote into specifics that move the number meaningfully.

Prices current as of 10 June 2026, taken from the live /weight-loss page. Hims iterates on this pricing structure frequently — new oral GLP-1 formats were added in 2026 — so re-verification before signup is warranted. We update this page when prices change.

Hims Weight Loss Membership (required for any GLP-1 medication)

Page footnote: "An active Hims Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership."

Medication pricing — on top of the membership fee, per month, if prescribed

The two-tier same-molecule pricing. The same drug — tirzepatide — appears on the Hims page at $299/month (Zepbound Vial or KwikPen, via the LillyDirect partner-pricing program) and at $1,899/month (branded Zepbound or Mounjaro through full retail). The six-fold gap reflects Eli Lilly's direct-to-consumer pricing program versus standard retail-pharmacy self-pay. Both are real prices, but the page does not explain the reason for the gap in plain language — the patient has to know about LillyDirect to understand why one tirzepatide is $299 and the other is $1,899. This isn't dishonest, but it isn't transparent either.

All-in monthly cost example. A patient on Wegovy Pen pays $39 (first-month membership) + $199 (medication) = $238 first month, then $149 + $199 = $348/mo thereafter. For Zepbound Vial via LillyDirect: $39 + $299 = $338 first month, then $149 + $299 = $448/mo thereafter. For full-retail Mounjaro: $149 + $1,899 = $2,048/mo. The "From $149/mo" footnote on the page hero is the lowest medication price (Wegovy Pill, Foundayo Pill, or Ozempic Pill) — patients who walk away with just that number in their head will be substantially mispriced.

Insurance / FSA / HSA. Hims's FAQ recommends using a credit/debit card and submitting for FSA/HSA reimbursement rather than running the FSA/HSA card directly at checkout. Insurance is not accepted.

The funnel is the standard cash-pay-telehealth template, with two distinctive features that follow from the public-company posture and the scale of the provider network.

Online intake. Detailed questionnaire covering symptoms, history, and treatment goals. Identity verification is required. The intake dynamically expands based on answers.

Provider review. A licensed provider on the Hims & Hers platform reviews the intake. Care is asynchronous by default — secure messaging back-and-forth rather than a live video or phone call — except in states that require live audio or video. This is structurally different from competitors who require synchronous video. The async model is genuinely faster for many patients but reduces depth of provider interaction.

Pharmacy fulfillment. Per the company's strategic pivot, the bulk of weight-loss medications now ship via manufacturer-direct programs (NovoCare Pharmacy for Novo Nordisk products, LillyDirect for Eli Lilly products). Compounded products in other categories (Hair Hybrids, custom Rx skincare, enclomiphene-based testosterone support) ship via partner compounding pharmacies. Hims also operates an Ohio pharmacy facility opened in 2020.

Shipping. Discreet packaging, free shipping included.

Ongoing care. Unlimited messaging with the care team through the Hims app or web portal. The company also operates a proprietary AI/ML decision-support tool called MedMatch (launched 2023), described as helping providers consider treatment options drawn from de-identified platform interaction data. MedMatch is a company-stated capability; there is no peer-reviewed independent validation of its clinical impact.

Hims's outcome claims are notably better-sourced than the compounded-DTC competitors we've reviewed. The headline weight-loss claim on the /weight-loss page is "Lose up to 25% body weight" with a footnote to Lancet Diabetes & Endocrinology 202500226-8/abstract "Source — Lancet Diabetes & Endocrinology 2025, S2213-8587(25)00226-8") — the STEP UP trial of semaglutide 7.2 mg/wk, an investigational higher-dose protocol. This is a real peer-reviewed primary trial in a top-tier journal, which is the appropriate evidence base for that magnitude of weight loss.

For standard-dose semaglutide, the relevant trial remains STEP 1, which found adults with overweight or obesity lost on average 14.9% of body weight at 68 weeks on once-weekly 2.4 mg semaglutide, versus ~2.4% on placebo. For tirzepatide, the SURMOUNT-1 trial showed larger average losses — into the 20%+ range at the higher doses over 72 weeks. Wegovy's cardiovascular benefit, expanded by the FDA in March 2024, is supported by the SELECT trial (n=17,604, NEJM 2023). Hims's marketing references SELECT explicitly.

A material caveat for hair products: while Hims's oral finasteride and oral minoxidil are FDA-approved (Propecia 1997 and Rogaine 1988 respectively), the "Hair Hybrids" line — topical finasteride + minoxidil sprays, serums, and chewables — are compounded products that are not FDA-approved. Hims discloses this on the hair-loss page in standard language. The active ingredients are well-evidenced at standard doses, but the specific compounded formulations Hims dispenses are not the studied products.

A material limitation for the AI-assist layer: MedMatch has no peer-reviewed independent validation. Hims describes it as a tool that helps providers consider different treatment options; whether MedMatch-supported care produces better outcomes than provider judgment alone has not been studied in the published literature. The marketing reads as if MedMatch is a clinical capability; the evidence base is operational, not clinical.

GLP-1 therapy is a well-characterized drug class with a consistent side-effect profile. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea, mild digestive discomfort — typically most noticeable during dose escalation and often easing with time. Less common but more serious risks include pancreatitis and gallbladder problems. The FDA-approved branded GLP-1s carry a boxed warning based on rodent studies of thyroid C-cell tumors and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnancy is a contraindication. Hims's product pages link to drug-specific Important Safety Information for each medication (Wegovy, Zepbound, Foundayo, Ozempic), which is appropriate given the company is dispensing FDA-approved branded products and the manufacturer-authored safety language applies directly.

Because Hims primarily dispenses branded FDA-approved GLP-1s rather than compounded versions, the compounded-quality concerns relevant at TeleZenMD, Henry, Mochi, and other compounded providers do not apply at the same scale here. This is the most meaningful safety differentiator in Hims's category positioning. (Hair Hybrids and enclomiphene-based testosterone support remain compounded, with the corresponding caveats.)

Asynchronous care is fast and convenient. It is also less interactive than live video for patients who genuinely benefit from real-time clinical conversation. Choose the model that fits your needs.

Hims's positioning inside the FDA compounding regulatory squeeze is materially different from the compounded-DTC providers we cover elsewhere. The FDA timeline — semaglutide and tirzepatide removed from shortage (Dec 2024 / Feb 2025), 503A and 503B grace periods ending in April and May 2025, the 503B Bulks List exclusion proposal of April 2026, and the public-comment deadline of 29 June 2026 — applies to compounded products. Hims has pivoted heavily out of compounded GLP-1 over the past 18 months and now dispenses these molecules predominantly as branded FDA-approved medications via manufacturer-direct partnerships.

The compounded categories where Hims retains exposure are smaller-scale: the Hair Hybrids line (topical finasteride + minoxidil combinations), enclomiphene-based testosterone support, and custom Rx skincare. These are subject to standard 503A compounding regulation, but they're not the subjects of the FDA's GLP-1-specific enforcement push.

For Hims's GLP-1 menu specifically, the regulatory deadline matters less than for compounded competitors — Hims's prescriptions are already on FDA-approved drug labels with manufacturer-supported supply chains.

Hims's menu is the broadest in our set. Selected entry pricing across categories:

The compounded-versus-FDA-approved mix on the hair page is worth highlighting. FDA-approved oral finasteride and oral minoxidil sit alongside compounded Hair Hybrids in the same visual product grid. The compounded disclosure ("Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Rx required.") appears at the bottom of the page; the per-product badges distinguish "FDA-approved" from "Rx" labels, but a casual scanner could miss the distinction.

Hims publishes a named medical advisory team prominently on its home page. We cross-checked four of the foregrounded advisors against the public NPI Registry on 10 June 2026 — all four are individually registered and actively licensed. Specialty mix spans Internal Medicine plus Obesity Medicine, Urology at a major academic medical center, Internal Medicine plus Endocrinology / Diabetes & Metabolism, and Internal Medicine plus Interventional Cardiology. The cardiology advisor is one of the most heavily-published interventional cardiologists in the U.S. — a level of advisory credentialing uncommon in DTC telehealth.

Two additional named MDs in corporate roles (Chief Medical Officer and Head of Medical Affairs) are foregrounded on the home page; NPI disambiguation for both was not run at the level required for this review and is listed as an open item. The public roster credentials Hims describes for those two are not independently verified here.

The cumulative effect is a more credentialed advisory layer than any compounded-DTC competitor we cover. Whether the advisory layer maps to the patient's actual prescribing visit — a typical Hims weight-loss visit is with one of 400+ network providers, not the foregrounded advisors — is a different question. The advisory roster signals company-level clinical seriousness rather than per-visit physician depth.

Reading the third-party signals. Hims sits at an unusual signal mix for the category. The Better Business Bureau lists Hims & Hers Inc. as accredited with an A+ rating — by some distance the strongest BBB signal of any provider we cover. Trustpilot, by contrast, shows a 3.0/5 rating across ~7,980 reviews for Hims (and 3.4/5 across ~7,099 for Hers), per Klarity Health's May 2026 comparison — meaningfully lower than the compounded-DTC operators (Mochi 4 stars, Henry 4.5 stars, TeleZenMD 4 stars). Different signals, different things measured; the BBB-versus-Trustpilot inversion vs. Henry/Mochi (where BBB is weak and Trustpilot strong) is real and worth flagging.

Pros.

BBB-accredited with an A+ rating. Hims & Hers Inc.'s BBB business profile shows BBB Accredited Business status and an A+ rating — the strongest BBB signal in our set.

Branded FDA-approved GLP-1 menu is the cleanest evidence base in our set. Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro — all on FDA-approved labels with manufacturer-supported supply.

Manufacturer pivot worked at the institutional level. Novo Nordisk filed a lawsuit against Hims in February 2026 alleging unlawful mass-marketing of unapproved compounded semaglutide. On 9 March 2026, Novo Nordisk dropped the lawsuit concurrent with the announcement of a strategic shift: Hims pivoting to selling branded Wegovy through the NovoCare partnership instead. The dispute resolved through a commercial partnership rather than continued litigation — a materially different outcome from the active Eli Lilly cases against the compounded-DTC competitors (Henry Meds, Mochi Health) where lawsuits remain unresolved.

LillyDirect and NovoCare partner pricing brings the headline med cost down meaningfully ($299/mo Zepbound Vial vs. $1,899/mo full retail). The partner programs are real value when they fit the patient.

Verified advisory layer is unusually credentialed for the DTC space. Four foregrounded medical advisors cross-checked against the NPI Registry — including an internationally-recognized interventional cardiologist, a board-certified endocrinologist, and a urologist at a major academic medical center.

Outcome claims footnote to peer-reviewed primary trials. The "up to 25% weight loss" headline cites the Lancet 2025 STEP UP trial; this is the appropriate evidence base, not a self-published retrospective.

Substantial public-company transparency. Hims & Hers Health, Inc. files 10-K, 10-Q, 8-K, and other reports with the SEC. Quantitative claims about customer counts, revenue, and operations can be verified against primary financial filings — a transparency option not available at private competitors.

Asynchronous care model is fast and convenient for patients who don't want a live video visit.

Hair regrowth has FDA-approved options. Oral finasteride and oral minoxidil are listed alongside the compounded Hair Hybrids; patients who want FDA-approved-only can pick from a clean menu.

Cons and trade-offs.

"From $149/mo" understates all-in cost. The membership ($39 first → $149 recurring) is foregrounded as a footnote, not as a headline number. Patients who calculate Wegovy Pen as "$199/mo" will be off by $149/mo every month after the first.

Same molecule at two prices on one page. Tirzepatide appears as $299/mo (Zepbound Vial via LillyDirect) and $1,899/mo (branded full retail) without plain-language explanation. Patients have to know about LillyDirect to understand the gap.

Trustpilot rating is 3.0/5. Lower than every compounded-DTC competitor in our set. The sample size (~7,980 reviews for Hims) is also smaller than at Henry or Mochi despite Hims's larger subscriber count, suggesting Hims's review-solicitation pattern is less aggressive (or less effective) than at compounded peers.

Active shareholder securities class actions. Rosen Law Firm and Kessler Topaz Meltzer & Check have filed federal securities fraud class actions on behalf of NYSE: HIMS shareholders. These are stock-disclosure-related claims, separate from product safety. The existence of such litigation is the typical price of public-company exposure, but it's a real ongoing matter readers should know about.

Compounded Hair Hybrids share visual space with FDA-approved finasteride. The compounded disclosure exists at the page bottom; the per-product badges are clear if you read them; the visual product grid does not strongly differentiate.

MedMatch AI marketed without published clinical validation. The decision-support tool is described as a clinical capability; no peer-reviewed independent evaluation has been published.

Asynchronous-by-default care reduces real-time clinical depth. Faster on average, less interactive than live video for patients who benefit from conversation.

Two corporate-role MDs (Chief Medical Officer / Head of Medical Affairs) are not independently verified in this review — NPI disambiguation pending. The other four foregrounded advisors are verified.

Hims makes the most sense for the patient who wants FDA-approved branded GLP-1 with a credentialed advisory layer, can budget around the membership-plus-medication structure, and values the option to verify any quantitative claim against Hims & Hers SEC filings. It fits people who'd rather take Wegovy or Zepbound through a partner-direct program than a compounded equivalent, who use multiple categories (GLP-1 + ED + hair + labs) and want one platform for all of them, and who are comfortable with async-by-default care.

Skip it if you're paying out of pocket for the cheapest possible compounded GLP-1 — Hims's all-in monthly ($338-$448 typical) is meaningfully higher than the compounded competitors in our set ($178-$278 typical at Mochi or Henry's monthly tier). Skip it if you specifically want live video with your prescribing provider every visit — Hims is async-by-default. Skip it if you want full transparency around AI-assisted clinical decisions — MedMatch is operationally novel but clinically unstudied. And if you want compounded-only hair products (rather than a mix), Hims's Hair Hybrids share the page with FDA-approved finasteride and minoxidil; a competitor with a pure compounded hair line might fit better.

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Hims's position is clear enough at this level.

Against the other branded-DTC operator (Ro), Hims offers a similar broad-menu structure, comparable named-advisor depth, and a clearer SEC-filings transparency story. Ro counters with celebrity ambassador presence (Serena Williams, Charles Barkley), a built-in insurance-check tool that Hims doesn't offer, and a private structure that some patients may prefer for privacy reasons. Against the compounded-DTC operators (TeleZenMD, Henry, Mochi, TrimRx), Hims is materially more expensive but operates on the cleaner branded-drug evidence base. Against testosterone-focused competitors (Maximus), Hims's testosterone offering is narrower (enclomiphene only, no FDA-approved TRT format), but the GLP-1 and broader weight-loss surface is more developed.

The clearest case for Hims over any of those alternatives is wanting FDA-approved branded GLP-1 from a credentialed public-company platform, with the budget headroom for the membership-plus-medication structure.

How we reviewed this. Pricing, programs, and process details were pulled directly from Hims's public pages in June 2026 (homepage, /weight-loss, /erectile-dysfunction, /hair-loss, /about/the-company). Corporate details — SEC ticker, CIK, HQ, fiscal year, SPAC origin, latest 10-K filing date — were verified against the SEC's EDGAR public filings index. Prescriber verification was conducted independently against the public NPI Registry for four of the six foregrounded medical advisors — all four individually registered and active with the credentials Hims describes, spanning Internal Medicine plus Obesity Medicine, Urology at a major academic medical center, Internal Medicine plus Endocrinology / Diabetes & Metabolism, and Internal Medicine plus Interventional Cardiology. NPI disambiguation for the two additional named MDs in corporate Chief Medical Officer and Head of Medical Affairs roles is pending and listed as an open item. The headline weight-loss claim (up to 25%) is footnoted by Hims to a peer-reviewed primary trial in Lancet Diabetes & Endocrinology (2025); we verified that the citation maps to STEP UP, the higher-dose semaglutide protocol. Standard-dose evidence anchors to STEP 1 (Wilding et al., NEJM 2021). Tirzepatide weight-loss evidence anchors to SURMOUNT-1 (Jastreboff et al., NEJM 2022) and SURMOUNT-5 (Aronne et al., NEJM 2025). Wegovy cardiovascular evidence anchors to SELECT (NEJM 2023). All Tier A peer-reviewed primary trials. Compounded products in Hair Hybrids, custom Rx skincare, and enclomiphene-based testosterone support are explicitly disclosed by Hims as non-FDA-approved. MedMatch AI is described factually as a company-stated capability without peer-reviewed validation; the public review does not propagate clinical claims about MedMatch.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Hims & Hers Health, Inc.

Editorial note: Informational only — not medical advice. FDA-approved branded medications and compounded medications carry different regulatory and clinical profiles; compounded medications are not FDA-approved. GLP-1, hair, sexual-health, and mental-health treatment decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.